Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
INSM Insmed	$105.90 +0.5%	$76.19	$60.40 ▼ $106.58	$20.00B	0.8	2.17 million shs	4.43 million shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$66.26 ▼ $131.98	$14.05B	0.69	1.58 million shs	N/A
TEVA Teva Pharmaceutical Industries	$17.12 +0.9%	$16.53	$12.47 ▼ $22.80	$19.46B	0.6	10.22 million shs	9.51 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
INSM Insmed	+0.46%	+5.60%	+56.82%	+38.30%	+54.76%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	+0.14%	+74.50%
TEVA Teva Pharmaceutical Industries	+0.94%	+1.32%	+1.03%	+9.21%	+3.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBT Global Blood Therapeutics	0.2681 of 5 stars	0.0	0.0	4.0	0.0	0.0	0.6
INSM Insmed	3.4788 of 5 stars	2.5	1.0	4.3	3.3	1.7	0.6
ITCI Intra-Cellular Therapies	0.9189 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
TEVA Teva Pharmaceutical Industries	4.429 of 5 stars	4.6	5.0	0.0	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
INSM Insmed	3.00	Buy	$106.80	0.85% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	42.79% Upside

Current Analyst Ratings Breakdown

Latest GBT, TEVA, ITCI, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00
6/11/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $119.00
6/11/2025	INSM Insmed	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$94.00 ➝ $109.00
6/11/2025	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $120.00
6/10/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/10/2025	INSM Insmed	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy
6/10/2025	INSM Insmed	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$100.00 ➝ $115.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
INSM Insmed	$363.71M	55.24	N/A	N/A	$1.60 per share	66.19
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
TEVA Teva Pharmaceutical Industries	$16.54B	1.19	$3.40 per share	5.04	$4.74 per share	3.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.51	0.87	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest GBT, TEVA, ITCI, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBT Global Blood Therapeutics	4.92	6.88	6.17
INSM Insmed	11.38	5.86	5.44
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBT Global Blood Therapeutics	N/A
INSM Insmed	N/A
ITCI Intra-Cellular Therapies	92.33%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GBT Global Blood Therapeutics	4.90%
INSM Insmed	3.00%
ITCI Intra-Cellular Therapies	2.60%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

GBT, TEVA, ITCI, and INSM Headlines

Recent News About These Companies

Retirement Systems of Alabama Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 25 at 3:43 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic ...

June 25 at 12:18 AM | finanznachrichten.de

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress - Nasdaq

June 25 at 12:18 AM | nasdaq.com

TEVA Teva Pharmaceutical Industries Limited - Seeking Alpha

June 25 at 12:18 AM | seekingalpha.com

Teva reports final analysis of migraine prevention trial of Ajovy

June 24 at 7:17 PM | msn.com

Whalen Wealth Management Inc. Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 23 at 6:00 AM | marketbeat.com

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

June 23 at 3:00 AM | globenewswire.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Holdings Reduced by QRG Capital Management Inc.

June 20, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 18, 2025 | finanznachrichten.de

Teva and Fosun Pharma partner on early-stage oncology drug

June 18, 2025 | pharmatimes.com

Janney Montgomery Scott LLC Raises Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 18, 2025 | marketbeat.com

Teva 2024 Healthy Future Report: Advancing Innovation and Collaboration

June 17, 2025 | csrwire.com

Teva Pharmaceutical Stock Surges Despite Recent Dip NYSE Composite

June 17, 2025 | kalkinemedia.com

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

June 17, 2025 | zacks.com

Teva to collaborate with Fosun Pharma for TEV-56278

June 17, 2025 | finance.yahoo.com

Teva and Fosun ink deal on TEV-56278 development

June 17, 2025 | thepharmaletter.com

GAMMA Investing LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 17, 2025 | marketbeat.com

Eliyahu Kalif Sells 55,775 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

June 16, 2025 | gurufocus.com

Handelsbanken Fonder AB Buys Shares of 15,792 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 16, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

June 16, 2025 | fool.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $24.44 Average Price Target from Brokerages

June 15, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBT, TEVA, ITCI, and INSM Company Descriptions

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Insmed NASDAQ:INSM

$105.90 +0.48 (+0.46%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$105.08 -0.83 (-0.78%)

As of 06/24/2025 06:07 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$17.12 +0.15 (+0.88%)

Closing price 06/24/2025 03:59 PM Eastern

Extended Trading

$17.12 +0.00 (+0.01%)

As of 04:22 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time